Program
maralixibat
Also written as “Maralixibat”, “LUM001” and “LUM001 (Maralixibat)”.
Its studies are mostly in Alagille Syndrome · Cholestasis, progressive familial intrahepatic 1 · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary · Intrahepatic Cholestasis of Pregnancy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mirum Pharmaceuticals | 193 open or running | phase 4since Sep 17, 2025 | Jul 16, 2013 | Jan 12, 2029phase 2 · NCT07823127 |
| Takeda | 20 open or running | phase 3since Sep 14, 2022 | Sep 14, 2022 | none ahead |
Also a collaborator on its studies: lumena-pharmaceuticals-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Jul 16, 2013.
- Apr 16, 2014Phase 2 study in Alagille SyndromeMirum Pharmaceuticals · NCT02117713 · 34 enrolled · United States, Canada
- Jun 9, 2014Phase 2 study in Alagille SyndromeMirum Pharmaceuticals · NCT02160782 · 31 enrolled · Australia, Belgium, France and more
- Dec 12, 2014Phase 2 study in Liver Cirrhosis, BiliaryMirum Pharmaceuticals · NCT02321306 · United States, United Kingdom
- Jun 10, 2015Phase 1 study in Healthy VolunteersMirum Pharmaceuticals · NCT02475317 · 84 enrolled · United States
- Nov 14, 2017Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT03353454
- Apr 1, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT03905330 · 93 enrolled · United States, Argentina, Austria and more
- Oct 1, 2019Phase 2 study in Bile Duct DiseasesMirum Pharmaceuticals · NCT04168385 · 52 enrolled · United States, Australia, Belgium and more
- Dec 2, 2019Phase 3 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT04185363 · 84 enrolled · United States, Argentina, Austria and more
- Aug 20, 2020Phase 2 study in Biliary AtresiaMirum Pharmaceuticals · NCT04524390 · 75 enrolled · United States, China, Germany and more
- Jan 25, 2021Phase 2 study in Cholestasis, progressive familial intrahepatic 1Mirum Pharmaceuticals · NCT04729751 · 27 enrolled · United States, Belgium, Brazil and more
- Sep 14, 2022Takeda's first studies: 2 phase 3 studiesNew to TakedaTakeda · NCT05543187, NCT05543174
- Aug 8, 2024Phase 3 study in Cholangitis, SclerosingMirum Pharmaceuticals · NCT06553768 · 90 enrolled · United States, Brazil, Canada and more
- Sep 17, 2025Phase 4 study in Alagille SyndromeMirum Pharmaceuticals · NCT07290257 · 230 planned · Belgium, France, Germany and more
- Aug 12, 2026Phase 2 study in Intrahepatic Cholestasis of PregnancyMirum Pharmaceuticals · NCT07823127 · 15 planned
Ahead
- Jan 12, 2029Primary completion: phase 2 study in Intrahepatic Cholestasis of PregnancyMirum Pharmaceuticals · NCT07823127
- Sep 22, 2030Primary completion: phase 4 study in Alagille SyndromeMirum Pharmaceuticals · NCT07290257
TargetBeta
“Ileal bile acid transporter inhibitor; Ileal bile acid transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC10A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| linerixibatrule | GlaxoSmithKline | phase 3 | 14 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07823127Intrahepatic Cholestasis of Pregnancy | 2 | Not yet recruiting | Mirum Pharmaceuticals | Jan 12, 2029 | 15 |
| NCT07290257Alagille Syndrome · Belgium, France, Germany and more | 4 | Recruiting | Mirum Pharmaceuticals | Sep 22, 2030 | 230 |
| NCT06553768Cholangitis, Sclerosing · United States, Brazil, Canada and more | 3 | Active, not recruiting | Mirum Pharmaceuticals | Jul 29, 2026 | 90 |
| NCT05543187Cholestasis, progressive familial intrahepatic 1 · Japan | 3 | Completed | Takeda | Sep 4, 2023 | 5 |
| NCT05543174Alagille Syndrome · Japan | 3 | Completed | Takeda | Oct 25, 2023 | 7 |
| NCT04729751Cholestasis, progressive familial intrahepatic 1 · United States, Belgium, Brazil and more | 2 | Completed | Mirum Pharmaceuticals | Dec 17, 2024 | 27 |
| NCT04524390Biliary Atresia · United States, China, Germany and more | 2 | Completed | Mirum Pharmaceuticals | Nov 7, 2023 | 75 |
| NCT04185363Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more | 3 | Completed | Mirum Pharmaceuticals | Apr 23, 2025 | 84 |
| NCT04168385Bile Duct Diseases · United States, Australia, Belgium and more | 2 | Completed | Mirum Pharmaceuticals | Sep 4, 2024 | 52 |
| NCT03905330Cholestasis, progressive familial intrahepatic 1 · United States, Argentina, Austria and more | 3 | Completed | Mirum Pharmaceuticals | Sep 1, 2022 | 93 |
| NCT03353454Cholestasis, progressive familial intrahepatic 1 | 3 | Withdrawn | Mirum Pharmaceuticals | Jun 15, 2020 | 0 |
| NCT02475317Healthy Volunteers · United States | 1 | Completed | Mirum Pharmaceuticals | Dec 1, 2015 | 84 |
| NCT02321306Liver Cirrhosis, Biliary · United States, United Kingdom | 2 | Withdrawn | Mirum Pharmaceuticals | Dec 2017 | 0 |
| NCT02160782Alagille Syndrome · Australia, Belgium, France and more | 2 | Completed | Mirum Pharmaceuticals | May 28, 2020 | 31 |
| NCT02117713Alagille Syndrome · United States, Canada | 2 | Completed | Mirum Pharmaceuticals | Jun 1, 2020 | 34 |
| NCT02061540Cholangitis, Sclerosing · United States, Canada, United Kingdom | 2 | Completed | Mirum Pharmaceuticals | Feb 2016 | 27 |
| NCT02057718Cholestasis, progressive familial intrahepatic 1 · United States, France, Poland and more | 2 | Completed | Mirum Pharmaceuticals | May 8, 2020 | 33 |
| NCT02057692Alagille Syndrome · United States, Canada | 2 | Completed | Mirum Pharmaceuticals | Nov 16, 2016 | 37 |
| NCT02047318Alagille Syndrome · United Kingdom | 2 | Completed | Mirum Pharmaceuticals | Jun 17, 2020 | 19 |
| NCT01904058Liver Cirrhosis, Biliary · United States, Canada, United Kingdom | 2 | Completed | Mirum Pharmaceuticals | Apr 2015 | 66 |
| NCT01903460Alagille Syndrome · United Kingdom | 2 | Completed | Mirum Pharmaceuticals | Feb 2015 | 20 |
How it is read
Names in the registry
- “Maralixibat”, 9 entries
- “LUM001”, 5 entries
- “LUM001 (Maralixibat)”, 4 entries
- “TAK-625”, 2 entries
- “Livmarli Oral Product”, 1 entry
Conditions, from the studies’ own filings
- Alagille Syndrome, 7 studies
- Cholestasis, progressive familial intrahepatic 1, 6 studies
- Cholangitis, Sclerosing, 2 studies
- Liver Cirrhosis, Biliary, 2 studies
- Intrahepatic Cholestasis of Pregnancy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.